Linsley Lab


Personalized medicine, which seeks to match the right drugs to the right patients at the right time, has been most successful in cases where there is a clear genetic linkage between a disease and a therapy. This is not the case for many diseases, including most immune-mediated diseases, which involve more complex genetics and require new approaches for development of personalized therapies.

Our goal is to develop and use cutting edge systems biology approaches to elucidate molecular signatures of complex immune diseases, including autoimmunity and cancer. We expect these signatures to elucidate fundamental mechanisms of disease and response to therapy; new pharmacodynamic, patient stratification, and treatment response biomarkers; and new therapeutic approaches.

Examples of new therapeutic approaches include combination therapies for type 1 diabetes (T1D) predicted from resistance mechanisms and molecular signatures generated by RNA sequencing (RNA-seq) of treated patient whole blood samples.

Peter Linsley

Peter Linsley, PhD

Member; Principal Investigator, Linsley Lab
View Full Bio

Lab Members

Shubham Bansal

Shubham Bansal

Intern, Linsley Lab
Brenda Norris

Brenda Norris

Administrative Assistant, Linsley Lab
Erin Witkop

Erin Witkop

Bioinformatics Post Doctoral Research Associate, Linsley Lab

Research Projects

Linsley Lab Res Proj Prev - Elucidating Immune Processes

Elucidating immune processes in tumors that affect patient survival and response to therapy

We are investigating whether Immune Checkpoint Inhibitor blockade in cancer treatment promotes the proliferation and survival of T cells specific for self-antigens and tumor antigens that ultimately contribute to adverse immune events or response to therapy.
View Project
Linsley Lab Res Proj Prev - Shared Germline like TCR

Shared germline-like TCR alpha chains in autoreactive CD4+ T cells in T1D

We found a class of autoreactive T cell receptors (TCRs) that share TCR TRA chains between individuals and that these TCR TRAs are elevated in new-onset T1D patients. We are investigating the role of these public TCRs in autoimmune and anti-infectious agent immune responses.
View Project
Linsley Lab Res Proj Prev - Exhausted CD8+ T Cell

Exhausted CD8+ T cell populations linked to beneficial response in T1D

Using next generation sequencing approaches we are investigating the T cell ancestry and phenotypes of exhausted CD8+ T cell populations that are associated with beneficial response to T cell depleting agents in T1D.
View Project

Related Stories

Blog Main Image - Microscope Sample Dark
December 14, 2022

Immunology to Change Lives: Where We're Going in 2023

BRI was formed with a clear plan: First, answer key fundamental questions about the immune system. Then, build on those answers to change lives. This is a very exciting time because we’re reaching that second stage of the plan.

Read Article
Blog Main Image - 2D Abstract Telemedicine Online Healthcare
September 14, 2022

Clues into Crohn's: Exploring Why the Immune System Attacks Beneficial Bacteria

Your gut is home to a huge community of bacteria called the microbiome. Some bacteria are good, some are bad — and some might hold the key to understanding an inflammatory bowel disease (IBD) like Crohn’s disease and ulcerative colitis.

Read Article
Blog Main Image - Researcher Woman Working Hood Glass
March 17, 2022

Exploring Alpha: Deep Dive into T Cells Unveils Possible Driver of T1D

A team led by Peter Linsley, PhD, and Karen Cerosaletti, PhD, recently uncovered a clue that could help solve the mystery of why and how T1D starts and maybe even open the door to new therapies that stop the disease.

Read Article


Science in Seattle Logo

Publication of the Week: Deep Immune Phenotyping Reveals Similarities between Aging, Down Syndrome, and Autoimmunity

Read publication ➡
News Journal Clin Immunol JCI

Type 1 Diabetes Discovery Opens Door to Game-Changing Treatment Strategies

Read More
Featured Tumor Microenvironment Cancer T-Cell

Benaroya Research Institute Receives $4.5 Million Grant to Predict Which Cancer Patients will Benefit from Immunotherapy

Read More